Trends in incidence, treatment and survival of gallbladder cancer; a nation-wide cohort study

E. de Savornin Lohman(Radboud University Nijmegen), Philip de Reuver(Radboud University Nijmegen), A.E. Braat(Leiden University Medical Center), Rob H.A. Verhoeven(Radboud University Nijmegen), Tessa J.J. de Bitter(Radboud University Nijmegen), Bas Groot Koerkamp, Frederik J.H. Hoogwater(University Medical Center Groningen), Joanne Verheij, Irıs D. Nagtegaal(Radboud University Nijmegen), Heinz‐Josef Klümpen(University Medical Center Groningen), R. Van der Post(Radboud University Nijmegen), Lydia G. van der Geest(Netherlands Comprehensive Cancer Organisation), Jeroen Hagendoorn(Utrecht University), Freek Daams(Maine Farmland Trust), Nadia Haj Mohammad(Utrecht University), M. de Boer(University Medical Center Groningen), Thomas van Gulik, P. van den Boezem(Radboud University Nijmegen), C. van Laarhoven(Radboud University Nijmegen), J. Erdmann(Amsterdam University Medical Centers)
HPB
January 1, 2020
10.1016/j.hpb.2020.04.391
Cited by 0

Related Papers

Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914